The Case for Expanding Access to Vision Therapy

Most families arrive at our offices after someone has already looked at their child’s eyes. The school screening was passed. The pediatrician’s note says vision is fine. And yet homework still takes three hours, the words still swim after a page or two, or an adult still has a headache by lunchtime.

That gap — between “the eyes are healthy” and “the visual system works comfortably for hours of near work” — is where vision therapy lives. Some of what it treats is supported by good randomized trials. Some of it is not. Anyone arguing for wider access, as we do, owes families both halves of that picture.

Key takeaways

• Convergence insufficiency is common at every age: roughly 13% of fifth- and sixth-graders in one US school study (Rouse et al., 1999), and 13.15% of university students aged 18 to 35 had a symptomatic binocular or focusing dysfunction (García-Muñoz et al., 2016).
• Office-based therapy for symptomatic convergence insufficiency in children is the best-supported use of vision therapy (CITT, 2008; Cochrane, 2020).
• It is not a treatment for dyslexia, ADHD or reading scores — the largest reading trial was negative (CITT-ART, 2019).
• Standard screenings are built to catch amblyopia and refractive error, not eye teaming and focusing (USPSTF, 2017) — and only 64.9% of US 3- to 6-year-olds have ever had vision testing by any provider at all (Kemper et al., 2011).

Our view, not a study finding: in our offices, cost and awareness are the barriers families actually hit — and they are the ones a practice can do something about.

What the evidence supports best

Convergence insufficiency (CI) — difficulty pulling and holding the eyes inward for reading, and the best-studied member of the binocular vision dysfunction group — is not rare, and it is not only a childhood problem. Among 175 randomly sampled Spanish university students aged 18 to 35, 13.15% had a symptomatic accommodative or binocular dysfunction, and CI was the single most common diagnosis at 3.43% (García-Muñoz et al., 2016). That matters for access, because adults rarely have anyone screening them at all. Studies of children, which use sign-based rather than symptom-only definitions, land in the same range or higher: about 13% of fifth- and sixth-graders in a US school-based study met a high-suspect or definite CI classification (Rouse et al., 1999), and a large Indian school study put non-strabismic binocular vision problems near 30%, with CI the most common — a different population and different criteria, so those numbers do not transfer directly to US children (Hussaindeen et al., 2017).

For symptomatic CI in children, office-based vergence/accommodative therapy with home reinforcement is the treatment with the strongest support. In the 221-child Convergence Insufficiency Treatment Trial, 73% were successful or improved after 12 weeks, versus 35% with an office-based placebo therapy and 33–43% with home programs (CITT, 2008). Among the children who became asymptomatic, 84.4% of the office-based group were still asymptomatic a year later (CITT, 2009). A Cochrane network meta-analysis of 12 trials and 1,289 participants confirmed the advantage over placebo in children (Scheiman et al., 2020), and the same therapy improved focusing amplitude by 9.9 dioptres versus 2.2 with placebo (Scheiman et al., 2011).

Amblyopia is the other well-studied piece. It affects about 1.44% of people worldwide and 2.41% in North America (Fu et al., 2020), and treatment is not only for toddlers: 53% of 7- to 12-year-olds responded to a combined program of patching, near visual activities and atropine, versus 25% with glasses alone (PEDIG, 2005). Worth being precise here: the well-studied treatment for amblyopia is patching and atropine, not vision therapy.

Who never gets checked, and who never gets followed up

Before any argument about what therapy can do, there is a plainer problem: a lot of people are never looked at. In a national US survey of 4,237 children, only 64.9% of 3- to 6-year-olds had ever had vision testing by any health provider — 42.9% at age 3, rising to 79.4% by age 6, so the youngest children, the ones with the most developmental runway, are the least likely to have been checked (Kemper et al., 2011). Follow-through is the second gap: the AOA’s pediatric guideline summarizes research in which only 38.7% of children who failed a school screening received follow-up care — that figure is the guideline’s summary of the studies it cites, not our own data (AOA, 2017). Why screenings are not designed to find eye teaming and focusing problems in the first place is covered in vision and learning and what school vision screenings miss.

The children whose symptoms get read as something else

Attention and vision complaints overlap. In one records review, 9.8% of patients with CI carried an ADHD diagnosis and CI appeared in 15.9% of ADHD charts (Granet et al., 2005). In a survey of 75,171 US children, an ADHD diagnosis was about twice as common when parents also described a vision problem that glasses or contacts could not fix — 15.6% against 8.3%, an adjusted odds ratio of 1.8 (DeCarlo et al., 2016). And children with symptomatic CI but no ADHD still had more parent-reported school behavior problems than children with normal binocular vision (Rouse et al., 2009).

Every one of those is an association, not a cause. The defensible conclusion is narrow and, we think, important: a child who avoids near work deserves a look at how the eyes work together before “won’t focus” is settled as the whole explanation.

Where the evidence stops

We will not oversell this. When the CITT team ran the larger follow-on trial specifically to test reading, therapy was no better than placebo: the two groups gained almost exactly the same amount of reading comprehension, a 3.7-point gain against 3.8 (CITT-ART, 2019). In that same trial, eye-teaming signs improved more with therapy while symptom scores improved about equally in both groups (CITT-ART, 2019).

The AAP, AAO, AAPOS and AACO joint statement holds that dyslexia is language-based, that a vision problem may make school harder without being the cause of dyslexia, and that neither vision therapy nor tinted lenses should be recommended as a treatment for a learning disability (joint statement, 2009; technical report, 2011). Optometric organizations take a different position — that vision problems often do interfere with learning and that optometric care is one part of multidisciplinary help (AAO/AOA, 1997). Population data sit closer to the first view: in 5,822 children, four of every five with severe reading impairment had normal ophthalmic function (Creavin et al., 2015). We walk through both positions, and what each visual skill does and does not do for schoolwork, in vision and learning.

Adult evidence is thinner too. In a randomized trial of young adults with CI, 42% of the therapy group met symptom-elimination criteria versus 31% with placebo, and more than half remained somewhat symptomatic (Scheiman et al., 2005).

The barriers families actually hit

Awareness is the first: in our offices, most families tell us no one has explained to them that eye teaming and focusing are separately testable. Cost is the second, and it is concrete. We are an out-of-network practice and payment is due at the time of service, so we try to remove every obstacle we can control — documentation for out-of-network reimbursement, HSA and FSA funds where your plan allows, payment plans and CareCredit, a discount for paying in full, Step Up for Students (Unique Abilities Scholarship) for eligible families, and scholarships we award to two patients each month. Our full pricing is published on the cost and price page, and we break the variables down in how much vision therapy costs.

The third barrier is fit. Expanding access does not mean recommending therapy to everyone; it means evaluating carefully and saying so when a program is not the right answer — see who is a good fit for vision therapy and our overview of what vision therapy is and how our vision therapy programs are structured.

Our clinical perspective

Here is where we land, stated as our own view rather than as settled science. A treatable, measurable, symptom-producing problem — convergence insufficiency being the clearest example — should not go undetected for years because acuity was 20/20 in a hallway screening. Finding it takes a comprehensive developmental vision evaluation, not a bigger claim about what therapy can fix.

If reading, homework, headaches or screen fatigue are a daily fight in your house, the useful next step is measurement. Start with our symptom checklist, learn what a developmental vision evaluation includes, or Schedule an evaluation at our Boynton Beach or Boca Raton office.